Compound Screening TRIZ Cases

Neuron-specific Thy1 promoters drive localized PTN overexpression in transgenic mice, producing accurate behavioral phenotypes for psychiatric drug screening.

Peptides modulate the SASPase-FLG2 complex shape for rapid, sensitive screening of skin cell regulators.

Screening method identifies biomarkers correlating with drug sensitivity, preventing wasted time on non-responsive patients.

Tau oligomer assays replace post-mortem histopathology to enable in vivo monitoring of Alzheimer's progression.

A microfluidic device simulates ischemia and reperfusion injury by modulating fluid flow through an internal chamber containing cell cultures.

Anti-EVI1 antibodies reduce AML recurrence by blocking ITGA6/ITGB4-mediated adhesion, lowering Ara-C side effects.

Intrauterine administration of pattern recognition receptor inhibitors targets spinal glial activation, resolving adverse effects from systemic NSAID use.

Segmented sensors with accessory proteins detect native condensates without disrupting their structure.

Slit2 polypeptides activate PKA pathways to promote fat browning, addressing limited therapeutic options for obesity and diabetes.

LSD inhibitors target cancer stem cell resistance to conventional therapies, preventing tumor recurrence.

Screening method using olfactory receptors to identify candidate substances that inhibit binding of odor-causing molecules.

Fluorophore-tagged AMPK constructs enable real-time monitoring of cellular energy states without indirect activation methods.

Micromachined ultrasonic transducer emits dual-frequency signals to image finger features at multiple depths.

Segmented SxIP peptides target EB proteins to enhance synaptic plasticity while resolving therapeutic applicability limits in neurodegenerative disorders.

Kinetic modulators alter kon and koff rates to extend residency time, reducing dosing frequency while maintaining reliable signaling inhibition.

Midkine inhibitors expand regulatory T cells, resolving the contradiction between disease management and immunological suppression in multiple sclerosis.

Multiplex assays measure chemokines CCL3, CCL5, and CCL18 in plasma samples to predict future acute coronary syndromes despite assay complexity.

Overexpressing NFIX in cloned stem cells accelerates glial differentiation, reducing induction time from months to weeks while maintaining high purity.

Specific 4E-BP1-derived peptides enable precise glycogen synthase kinase 3 activity measurement through targeted phosphorylation events.

Targeted peptides disrupt the CaMKII-HDAC4 interaction, preventing nuclear export of HDAC4 and reducing hypertrophic gene activation.

Detection of STING promoter methylation status enables demethylating agent selection to restore immune signaling in tumors.

SELDI mass spectrometry measures multiple protein biomarkers to resolve sensitivity and specificity limitations of single-marker tests.

CRISPR/Cas9 editing activates endogenous RTP1, resolving inefficient cell line development by enabling stable protein expression for high-throughput screening.

Pre-coated compound arrays eliminate pipetting steps, reducing assessment time while maintaining measurement precision.

Beta-amino acid substitution extends half-life while maintaining VIP receptor selectivity, resolving stability versus binding adaptability trade-offs.

Arachidonic acid metabolites diagnose senescence, resolving precision and reliability contradictions in traditional markers.

Small molecule inhibitors disrupt the CD19-PI3K interaction to reduce Myc protein levels in B-cell neoplasms.

EnSeMBLE generates structural ensembles of alpha helical membrane proteins to resolve flexibility constraints and enable selective ligand binding.

A method measures partition characteristics, binding affinity, and phase boundary properties to identify compound interactions with biological condensates.

Specific STING modulators enhance anti-tumor immunity while reducing autoimmune responses through selective pathway interaction.

A genetically-encoded Rex biosensor converts intracellular redox states into proportional fluorescent signals via allosteric transcription factor dynamics.

Screening methods identify substances inhibiting netrin-4 signaling to treat neuropathic pain resistant to conventional analgesics.

A cell partitioning method uses reporter oligonucleotides to link antibody binding events to barcoded nucleic acid molecules for rapid sequencing analysis.

Targeting DNA repair pathways in AID-expressing cancer cells reduces tumor burden while sparing healthy tissue from chemotherapy damage.

Nested aqueous two-phase system protects cell aggregates from evaporation and osmotic stress, enabling reliable high-throughput drug screening.

Kinase inhibitors block PI3K and Src pathways to prevent cancer stem cell emergence, overcoming acquired chemotherapy resistance.

Compound 14 irreversibly inactivates DNA polymerase beta through selective covalent modification of specific lysine residues within the enzyme active site.

A flow cytometry platform analyzes tumor regenerative hierarchies and cell cycle phases using vital membrane fluorophores and DNA binding dyes.

CaMKKβ inhibitors block androgen signaling, overcoming resistance in advanced prostate cancer.

Segmenting the fluorophore from the peptide substrate reduces synthesis complexity while maintaining high sensitivity and stability in cellular environments.

Inactivated fluorescently-labeled viruses enable rapid antibody neutralization measurement via flow cytometry, eliminating live virus safety hazards.

Human pluripotent stem cells differentiate into mesendoderm to measure lineage markers for compound assessment.

Engineered mutant human estrogen receptor alpha with tryptophan to phenylalanine mutations enables fluorescence-based detection of therapeutic agent effects.

Screening substances that promote induced pluripotent stem cell induction from patient cells using specific chemical inhibitors.

Inducible promoters control AS160-like protein expression to identify therapeutics that address molecular insulin resistance mechanisms.

Laser micro-irradiation induces localized DNA damage to quantify protein trapping via fluorescence, enabling specific cancer cell killing.

FRET-based screening identifies inhibitors disrupting EF-Tu and tRNA binding to overcome gram-negative bacterial resistance.

Synthetic peptides bind conserved IL1RAP residues to block receptor interactions and induce leukemia cell apoptosis.